TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26655100
Drug: Active balance
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active balance exercises (progressive, highly challenging group exercise program, twice weekly for 90 minutes)
Study: 25234605
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (DE)
Study: 4684623
Drug: Marijuana cigarette
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana cigarette containing 4.8 mg Delta(9)-THC
Study: 4684623
Drug: Marijuana cigarette
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana cigarette containing 9.1 mg Delta(9)-THC
Study: 7976985
Drug: Prophylactic aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic aspirin therapy
Study: 7976985
Drug: Nicotine substitutes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine substitutes as adjunctive therapy in smoking cessation
Study: 7976985
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy following myocardial infarction
Study: 7976985
Drug: Anti-inflammatory agents
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory agents in the treatment of asthma
Study: 7976985
Drug: Antidepressant drugs
Normalized name: MAO A Inhibitors, antidepressant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant drugs as therapy for mild depression
Study: 29068266
Drug: Weekly general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly general support (Control)
Study: 26631904
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine extract of onion (RO) (250 mL for 10 weeks)
Study: 26631904
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (RW) (250 mL for 10 weeks)
Study: 25085534
Drug: Anticholinergic drugs
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drugs (most frequently in haloperidol group)
Study: 17852312
Drug: Power-assisted functional
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Power-assisted functional electrical stimulation (FES) therapy
Study: 9267580
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment without expansion
Study: 3509066
Drug: 5-mg melatonin
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg melatonin
Study: 22493073
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 to 50 mg
Study: 22493073
Drug: Amiloride (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (10-20 mg)
Study: 22493073
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 to 10 mg)
Study: 17463213
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 2 mg + oral aprepitant 125 mg
Study: 9378843
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 2 mg
Study: 11104314
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (Beh) group (unmedicated)
Study: 9314913
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized E2 (2 mg daily)
Study: 8393365
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (ara-C) as a repair inhibitor of cyclophosphamide (Cy) resistance
Study: 2873131
Drug: Alprazolam (3.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (3.67 mg)
Study: 2873131
Drug: Imipramine (167
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (167 mg)
Study: 18502262
Drug: Fenofibrate (FENO)
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate (FENO) 160 mg/day
Study: 28625503
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) 10 mg/day
Study: 17333838
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using delta‐aminolevulinic acid in a water‐in‐oil emulsion applied to lesions, repeated once a week for a month
Study: 12804082
Drug: Throat Coat
Normalized name: Menthol 2.5 mg ORAL PASTILLE [Throat Coat]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Throat Coat (5-8 oz, 4-6 times daily)
Study: 12804082
Drug: Placebo (5-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5-8 oz, 4-6 times daily)
Study: 31839677
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus MEK inhibitor selumetinib
Study: 19556637
Drug: Lacto-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacto-G
Study: 18555932
Drug: S(‐)‐amlodipine nicotinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(‐)‐amlodipine nicotinate 2.5 mg QD
Study: 18555932
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate 5 mg QD
Study: 8067483
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment
Study: 11074998
Drug: Graftskin plus
Normalized name: GRAFTSKIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graftskin plus compression therapy
Study: 6791596
Drug: Nebulised sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised sodium cromoglycate (20 mg four times daily)
Study: 6791596
Drug: Oral choline
Normalized name: choline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral choline theophyllinate (6.7 mg/kg four times daily)
Study: 28215136
Drug: Systematic prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic prevention and treatment of fever
Study: 21885077
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of albendazole (400mg)
Study: 21885077
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of mebendazole (500mg)
Study: 21885077
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of albendazole (400mg) and mebendazole (500mg)
Study: 21885077
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of albendazole (400mg/400mg)
Study: 21885077
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of mebendazole (500mg/500mg)
Study: 21885077
Drug: Single drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drugs (albendazole or mebendazole)
Study: 21885077
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (albendazole + mebendazole)
Study: 19703830
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily
Study: 19703830
Drug: Good adherence
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good adherence (>80% use of study medication)
Study: 17854028
Drug: MYP (myeloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYP (myeloid cell purging system) during treatment interruption
Study: 14973305
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg q8h with rifabutin 300 mg qd
Study: 3348966
Drug: PUVA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA treatment for 14 days
Study: 31802233
Drug: Needle group
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle group (20 ml of 0.5% ropivacaine via needle)
Study: 20681818
Drug: Gel
Normalized name: Gel
DrugBank: Sepia esculenta bone (DB16562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel
Study: 26148007
Drug: Ad35.CS.01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad35.CS.01 vaccine followed by two doses of RTS,S/AS01 (ARR-group)
Study: 26148007
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of RTS,S/AS01 (RRR-group)
Study: 24019080
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) at 160/80/40 mg every two weeks
Study: 24019080
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) at 2 mg/kg/day
Study: 24019080
Drug: Mesalamine at
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine at 3 g/day
Study: 9425965
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg bupivacaine
Study: 10551572
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ropivacaine
Study: 10551572
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg ropivacaine
Study: 10551572
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg ropivacaine
Study: 6837621
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 mg daily)
Study: 6837621
Drug: Prazosin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (15 mg daily)
Study: 6837621
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonidine and prazosin
Study: 27062079
Drug: Tapentadol prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol prolonged release (PR) 100-250 mg bid
Study: 30660342
Drug: Trigger Point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger Point Injection (TPI)
Study: 28845548
Drug: Topical adhesive
Normalized name: menthol TOPICAL ADHESIVE PATCH, MEDICATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adhesive pads
Study: 23739758
Drug: Osteopathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manual treatment (OMT)
Study: 23739758
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (UST)
Study: 10778966
Drug: Preoperative irradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative irradiation therapy (five doses of 5 Gy each)
Study: 8730606
Drug: 320 ml
Normalized name: PYRITHIONE ZINC 6.4 g in 320 mL TOPICAL SHAMPOO [HAIRJOY MSM HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 ml of red wine (providing 30 g/day of alcohol)
Study: 8730606
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day of alcohol diluted in 320 ml of clear fruit juice
Study: 8730606
Drug: 320 ml
Normalized name: PYRITHIONE ZINC 6.4 g in 320 mL TOPICAL SHAMPOO [HAIRJOY MSM HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 ml of dealcoholised red wine
Study: 1523877
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (12.5 ng)
Study: 1523877
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (25 ng)
Study: 1523877
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (6.3-25 ng)
Study: 1523877
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (12.5 ng and 25 ng)
Study: 1335640
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine
Study: 28855226
Drug: Antibiotic (cephalexin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic (cephalexin if <6 months or co-trimoxazole if >6 months old) administered a day prior to VCUG and continued for 1 day post VCUG
Study: 19080672
Drug: oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral metronidazole sustained release tablet 750 mg/day for 7 days and vaginal tinidazole 250 mg for 7 days
Study: 19080672
Drug: oral tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tinidazole 1 g/day for 3 days (2 g for the first dose)
Study: 19080672
Drug: oral ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ornidazole 2 x 500 mg/day for 3 days and vaginal tinidazole 250 mg for 7 days
Study: 19080672
Drug: oral ornidazole
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ornidazole 2 x 500 mg/day for 3 days
Study: 19080672
Drug: oral secnidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral secnidazole 2 g in a single dose and vaginal tinidazole 250 mg for 7 days
Study: 9722127
Drug: oral secnidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral secnidazole 2 g in a single dose
Study: 7965311
Drug: Postoperative instructions
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative instructions with descriptive information regarding potential sequelae and analgesic use
Study: 3309236
Drug: Inhaled amikacin
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amikacin (100 mg twice a day) as adjunct to intravenous ceftazidime (250 mg/kg/day) and amikacin (33 mg/kg/day)
Study: 3309236
Drug: Intravenous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous therapy only (ceftazidime 250 mg/kg/day and amikacin 33 mg/kg/day)
Study: 3309236
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (inhaled amikacin and intravenous therapy)
Study: 16817045
Drug: Initial medical
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial medical treatment
Study: 2565266
Drug: Ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine plus bromazepam (300 mg ranitidine and 6 mg bromazepam)
Study: 2565266
Drug: Ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine plus placebo (300 mg ranitidine and placebo)
Study: 28421246
Drug: Intravenous polyspecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous polyspecific immunoglobulin G (IVIG) 25 g once daily for the first 3 days
Study: 28421246
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline) equal volume once daily for the first 3 days
Study: 19337810
Drug: Intraarticular hyaluronate
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular hyaluronate injection
Study: 16924992
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐Pop (APL, 3M ESPE)
Study: 11213852
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of citalopram 40 mg plus placebo
Study: 11213852
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ketoconazole 200 mg plus single dose of citalopram 40 mg
Study: 31158560
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) plus standardised medical care
Study: 19268383
Drug: Continual insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continual insulin injection
Study: 19268383
Drug: Continual secretagogue
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continual secretagogue administration
Study: 16854236
Drug: Unsupervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised treatment with artemether-lumefantrine (A/L)
Study: 12700619
Drug: Multi‐micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi‐micronutrient supplementation (3.5 g/l)
Study: 9876348
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg i.v.)
Study: 30982443
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (300,000 IU, single muscular injection)
Study: 30982443
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1 ml, Placebo group)
Study: 23375496
Drug: Dexamethasone 0.4
Normalized name: dexamethasone 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.4 mg/kg preoperatively
Study: 17010635
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution at 20 degrees C
Study: 17010635
Drug: Topical papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical papaverine at 20 degrees C
Study: 17010635
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution at 37 degrees C
Study: 15543714
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene 0.1% gel or cream once daily for 12 weeks
Study: 15543714
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene cream formulation
Study: 15543714
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene gel formulation
Study: 11758661
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment package
Study: 18046975
Drug: Amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5-10 mg once daily
Study: 9156363
Drug: Felodipine extended‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine extended‐release 5-10 mg once daily
Study: 26411504
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNS) containing 90 µg I with 0 or 10 mg Zn, 20 g/day from 9 to 18 months of age.
Study: 21410297
Drug: Orally dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally dosed non-(14)C-labeled lesogaberan (100 mg)
Study: 16448895
Drug: candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: candesartan 8 to 16 mg
Study: 12562705
Drug: Tablets 500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets 500/125 mg
Study: 12562705
Drug: Tablets 875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets 875/125 mg
Study: 12562705
Drug: Oral suspension
Normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension 250/62.5 mg per 5 mL
Study: 11524325
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine injection
Study: 9007884
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no epidural morphine)
Study: 8513309
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg o.d. (doubled after 1 month if seated diastolic BP was > or = 95 mmHg)
Study: 8513309
Drug: Potassium-Canrenoate (K-Can)
Normalized name: potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-Canrenoate (K-Can) 50 mg o.d. (doubled after 1 month if seated diastolic BP was > or = 95 mmHg)
Study: 8513309
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (HCTZ and K-Can)
Study: 2872804
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 to 40 mg once daily)
Study: 28926353
Drug: Lacosamide 200
Normalized name: lacosamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide 200 mg
Study: 17120972
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose Vi polysaccharide vaccine (Typherix)
Study: 17120972
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control hepatitis A vaccine (Havrix)
Study: 11275505
Drug: General practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practice methadone maintenance treatment
Study: 9284777
Drug: hPTH [1-34],
Approvals — FDA: no, EMA: no, PMDA: no
Description: hPTH [1-34], 400 U/25 micrograms daily subcutaneously
Study: 9284777
Drug: Hormone-replacement therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-replacement therapy only (Control)
Study: 27511844
Drug: Cetux‐FHX (cetuximab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetux‐FHX (cetuximab, 5‐fluorouracil, hydroxyurea, and 1.5 Gy twice‐daily radiation therapy every other week to 75 Gy)
Study: 27511844
Drug: Cetux‐PX (cetuximab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetux‐PX (cetuximab, cisplatin, and accelerated radiation therapy with delayed concomitant boost to 72 Gy in 42 fractions)
Study: 17226852
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy in children on concomitant corticosteroids